1. Home
  2. XLO vs PDSB Comparison

XLO vs PDSB Comparison

Compare XLO & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$0.65

Market Cap

41.8M

Sector

Health Care

ML Signal

HOLD

Logo PDS Biotechnology Corporation

PDSB

PDS Biotechnology Corporation

N/A

Current Price

$0.77

Market Cap

49.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XLO
PDSB
Founded
2016
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.8M
49.5M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
XLO
PDSB
Price
$0.65
$0.77
Analyst Decision
Buy
Strong Buy
Analyst Count
1
2
Target Price
$2.00
$9.00
AVG Volume (30 Days)
527.5K
583.3K
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$31,804,000.00
N/A
Revenue This Year
$626.78
N/A
Revenue Next Year
$79.08
N/A
P/E Ratio
N/A
N/A
Revenue Growth
588.40
N/A
52 Week Low
$0.62
$0.70
52 Week High
$1.70
$2.20

Technical Indicators

Market Signals
Indicator
XLO
PDSB
Relative Strength Index (RSI) 35.65 44.55
Support Level $0.65 $0.76
Resistance Level $0.68 $0.93
Average True Range (ATR) 0.03 0.06
MACD 0.00 -0.01
Stochastic Oscillator 17.98 22.29

Price Performance

Historical Comparison
XLO
PDSB

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.

About PDSB PDS Biotechnology Corporation

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Share on Social Networks: